NervGen Pharma Corporation (NGEN)

NervGen Pharma: I Think The Biggest Risks Are Now Behind It
Jul 02, 2026, 12:25 PM ETNervGen Pharma Corp. (NGEN) StockXBI

Grassroots Trading

Summary
• NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial.
• NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting focus to NVG-291’s ability to replicate efficacy in chronic tetraplegia.
• Objective biomechanical gait analysis showed statistically significant improvements, reinforcing the case for NVG-291’s neural recovery over compensatory adaptation.
• With a risk-adjusted equity value of $7.50–$8.50 per share, NGEN offers significant upside if Phase 3 results mirror prior CONNECT SCI data.

Thesis
This marks the third time I'm covering NervGen Pharma (NGEN), a clinical-stage biotechnology company developing regenerative treatments for spinal cord injury. To date, I've been bullish on this high-risk stock because NVG-291 could become the first approved treatment to help patients with chronic tetraplegia regain meaningful function. NervGen is not as undervalued as it was a few months ago, but given the lower regulatory, financing, and execution risks, I still believe the stock is a good buy based on the potential upside if its clinical trials succeed.
From Scientific Promise to Clinical Execution
In my last coverage of NervGen, NVG-291’s evidence was the main point of discussion for NervGen shareholders. This is no longer the case. The focus is now more on execution. The science still needs to be tested in a registrational trial. However, most of the uncertainties outside of Phase 3 have been materially reduced.
A major milestone was the company’s successful End-of-Phase 2 meeting with the FDA, which resulted in consensus on the design of the RESTORE registrational study. Instead of carrying uncertainties around endpoints, dosing, and study design as it moves into late-stage development, NervGen now has FDA alignment on the design of a randomized Phase 3 trial enrolling approximately 150 patients with chronic tetraplegia. Management stated that CONNECT SCI data directly informed endpoint selection and trial design. Considering where the company was a few months ago, these developments significantly reduced regulatory uncertainty.
And NervGen appears more mature operationally.
In Q1, NervGen added leadership in finance, regulatory affairs, and patient advocacy to its executive team. This coincided with NervGen’s Nasdaq transition and preparation of RESTORE clinical sites. CEO Adam Rogers noted the company is “firmly in execution mode.” From my angle, this seems justified since site activation is already underway and NervGen is on target to start Phase 3.
Management has also tackled what is probably the most significant practical shareholder issue: funding.
The public offering in May raised approximately $60 million to fund the registrational program and removed the biggest near-term concern. Naturally, shareholders would prefer zero dilution, but that was always on the table. Besides, financing risk is different from clinical risk. The point is, I and other shareholders included are no longer wondering if NervGen has the funding to start Phase 3. Instead, the discussion has narrowed to if NVG-291 can reproduce the same results in the pivotal study.
Better Data, Better Commercial Odds
What changed in the past few months was the type of evidence produced by NervGen. One of the biggest challenges in spinal cord injury research has been telling the difference between real recovery of the nervous system and the body's ability to compensate by finding other ways to perform the same movement or function. That is, neuropathically injured patients sometimes perform learned movements without repairing the damaged neural pathways. The distinction of the two processes makes a major difference here because regulators and physicians and, thereafter, payers need the confidence that the development of any functional improvement will not be an adaptive response.
So, I think the company’s independent, blinded biomechanical gait analysis deserved more attention. Rather than focusing only on conventional clinical tests, the analysis measured how well people coordinated their movements, how much physical effort it took to walk, and how well they maintained balance and posture. It used objective motion capture and a Global Statistical Test to evaluate these measurements.
Patients who received NVG-291 showed statistically significant improvement on the composite assessment (p=0.0197). All patients administered NVG-291 were classified as responders, compared with only one patient in the placebo group, and NVG-291 patients showed improvements in walking speed without an increase in mechanical effort. This circles back to my previous point that this likely demonstrates that the improvement in walking speed was the result of better neural control and not secondary compensation due to the injury. These results also support earlier documented improvements in electrophysiological signaling, upper-limb function, independence, and quality of life, which provide a much more consistent efficacy package than investors had a few months ago.
Wall Street also appears to be responding more seriously to that evidence as well.
Last month, TD Cowen began coverage of the stock with a Buy rating after speaking with some key opinion leaders and walked away with an opinion that a successful launch might support peak annual sales of $1.1 billion. Generally speaking, I try not to put too much stock in the opinion of one analyst. Still, the report does stand out to me because it suggests institutional analysts are starting to view NervGen less like an early-stage science project and more like a company with a clear commercial opportunity. Of course, that doesn't make the upcoming Phase 3 trial any less risky.
Another thing that's working in NervGen's favor doesn't have to do specifically with NVG-291. The current setting in comparison to last year for development-stage biotech is much better. For instance, capital is returning to biotech.

Seeking Alpha
Over the past year, the SPDR S&P Biotech ETF (XBI) experienced nearly $1.3 billion in net inflows and almost a doubling since the 2025 lows. At the same time, acquisitions have picked up as large pharmaceutical companies continue looking for new drugs and technologies to add to their pipelines before major patents on their existing products expire.
Perhaps even more importantly for companies like NervGen, investors seem to be placing more value on companies that are close to pivotal clinical trials and have clinical data that clearly set them apart from competitors. I believe NervGen’s fit to the market is much stronger now than it was a couple of years ago. If NervGen was at this point during the biotech downturn, raising enough capital to launch a registrational trial likely would have come at a much steeper cost to shareholders.
Risk And Valuation

Seeking Alpha
Keep in mind, valuing NGEN has always been a high-risk proposition since the company has no revenue, no earnings, and generated an operating cash outflow of roughly $16.9 million over the trailing twelve months.
Relatively traditional metrics such as P/E, EV/Sales, and price-to-book would be of little use here. Instead, I continue to rely on a risk-adjusted framework built around the commercial potential of NVG-291.
I've changed three assumptions as compared to my previous models. First, I believe the probability of success has increased after the FDA’s alignment on Phase 3 of the RESTORE study, in addition to the other independent biomechanical data. Second, the May financing dealt with a near-term funding risk.

Seeking Alpha
Even so, we know that it came with a cost: shares increased to roughly 81 million. Finally, there has been a positive change in how the commercial opportunity is being viewed. While my previous model assumed peak annual sales of about $700 million, I can now increase that estimate significantly based on Wall Street's projection that NVG-291 could generate approximately $1.1 billion in peak annual sales if it reaches the market.
Factoring in a more moderate peak sales estimate of approximately $900 million, a conservative 5× peak sales multiple typical of orphan and specialty biotech companies, a 50% probability of approval, and a 12% discount rate applied to peak commercialization value, I estimate an equity value of approximately $600–700 million, or roughly $7.50–$8.50 per share using approximately 81 million shares outstanding. That represents significant potential upside from the current price, and the recent share price decline has improved the risk-reward profile, especially since NervGen’s regulatory, financing, and commercial outlook has strengthened since my last coverage.
Rating: Buy
The biggest unknown is Phase 3. I think the stock is still undervalued if the RESTORE trial backs up what was seen in the CONNECT SCI trial. Especially the functional improvements with supporting objective biomechanical evidence. If the RESTORE trial doesn’t deliver, well, then all that value disappears. This has always been a high-risk, all-or-nothing situation for the very small portion of my portfolio, maybe yours too, that justifies its place, but I don’t see the deep mispricing to support that more aggressive approach as strongly as before.

Great new interview with Adam Rodgers

https://open.spotify.com/episode/5SRiXPpCK6DiA5ZUxeWgxR?si=Tpup1dD5Q3ibDCLxcTKuBQ

Fingers crossed the FDA does the right thing and grants accelerated access to be included with the phase3.
322m mkt cap is small for the potential of diseases this can address. The big picture is SCI + MS+ Stroke + TBI + + + + + + +

This is the problem with the clinical trial process.
IF they are showing signs of success, IF there are
side effects, but 'minor' like shot site flaring up.

Why now allow them to do a 'phase 4' type of trial vs
running a PH 3. They could start 'treating' folks who are
willing to 'try' and record the observations as 'clinical' data
(redefine what and how its collected for each one trying it.
Won't be perfect, but if someone can't walk 10 meters, and then
can, who cares how long it took him for example.
Or couldn't open their hand for years, but now can? Who cares
how far he can, if he can flatten his palm, et al

I was kind of wondering if the fdA might work with them to speed up
the potential approva IF visible results are being seen.

But alas, this is the current timeline which of course likely means the
current share count of 80 Mil goes up (ATM) due to a need for funding
in order to survive till the trial is over in the 1st half of 2028. This is just
too long for something they are already seeing results that can't be
challenged.

Prepare for Pivotal Phase 3 Study Initiation: Expected Mid-2026
• Expected Completion of Enrollment in 2H 2027 with Topline Data in 1H 2028

Disclaimer: been a long time since i owned any, dilution and getting in way too early
aren't a winning combination. And hate it when the Market Cap gets run up this early..

Wings of Life Interview
https://vimeo.com/1145146133/b82092bd2c?share=copy&fl=sv&fe=ci

Have tracked NGEN(f) for a few years now. In their investor
deck is several 'testimonials' from clinical trial participants.
An end of PH 2 meeting with the fda 1st half of 2026.
Been telling myself, IF this showed effectiveness? Minimal
side effects by the end of the PH 2?

What would the odds be for something with the potential to seriously
impact folks lives in a very good way, not needing a full PH 3, maybe
even not needing a PH 3 to get approved. And running a PH 3 as a
confirmation data gathering effort post approval instead of denying this
potential treatment for another likely 1 1/2 to 2 years to do a PH 3??

disclaimer: don't own any. Concern over a couple of aspects:
Market cap already sitting at $430 Mil based on around 80 Mil
shares. $11 Mil or so in cash on hand (will they need more dilution?)
Chance for a buyout??

To close, like what I am seeing, but what is the fda giong to say in response
to the results. Cause having to develop and run a PH 3... Good luck..

NGENF changed to NGEN. Moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

NASDAQ listing approval

https://www.sec.gov/Archives/edgar/data/1751912/000135445726000019/8A_Cert_NGEN_0001751912.pdf

Forbes article--today

https://www.forbes.com/sites/the-prototype/2025/12/19/this-companys-drug-may-help-regenerate-injured-spinal-cords/

N I C E !!!

https://nervgen.com/nervgen-pharma-announces-expanded-connect-sci-study-data-demonstrating-unprecedented-durable-improvement-in-function-independence-and-quality-of-life-in-chronic-spinal-cord-injury/

Seems that NVG-291 checks several boxes that could make this Natl Priority Voucher Prog happen??

https://www.americanactionforum.org/insight/assessing-the-fdas-commissioners-national-priority-voucher-program/

3rd QTR update

https://nervgen.com/nervgen-pharma-reports-third-quarter-financial-results-and-provides-business-updates/

SCI Website Update:
https://www.sciventures.com/portfolio/nervgen-pharma

NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
https://nervgen.com/nervgen-pharma-announces-closing-of-us10-million-non-brokered-private-placement-to-support-anticipated-nasdaq-listing-and-advance-nvg-291-development/

THE DRUG WORKS!! Another patient testimonial!!!
https://www.newsbreak.com/times-leader-563611/4350500355187-it-works-it-really-works-kingston-woman-part-of-clinical-drug-trial

NVG-291 Recipient on CBS news!

https://stocktwits.com/Buckeye250/message/634781456

https://www.labiotech.eu/in-depth/spinal-cord-injury-treatment/

Testimonials just keep getting better:
https://www.yahoo.com/news/articles/paralyzed-man-walks-again-experimental-110022991.html

Another trial participant with with a fantastic testimonial:
https://stkt.co/R1UzpenZ

New video on NGEN with Dr. Adam Rogers

Bingo! Life changing stock!
NerveGen will very likely be huge!
Eventually.

With the recent news releases i am sure we see new highs sooner than later! Life changing stock

NGENF is a real sleeper. Eventually this will likely be huge.
Buy and hold. Accumulation mode….

More validation this works!
https://nervgen.com/nervgen-pharmas-nvg-291-r-demonstrates-significant-functional-recovery-in-department-of-defense-sponsored-preclinical-models-of-traumatic-hearing-loss-and-peripheral-nerve-injury/

New Blink of an eye episode featuring Brad Lang:
https://podcasts.apple.com/us/podcast/276-understanding-the-chemistry-of-nvg-291s-efficacy/id1526474466?i=1000722778980

The drug works. Participants from the last Phase 2 trial have reported unprecedented, lasting improvements that continue to progress. This is a life-changing stock trading at an extraordinary discount. I’m thrilled to have bought at these levels, especially with the risk dramatically reduced by the positive Phase 2 data. Investment community is sleeping hard on this one.

Mike Kelly on BNN post phase2 results. NGEN starts at 6:20min:


Chen Lin post Phase2 results:

The drug works. This is a scientific breakthrough! It’s early in the trials. NGEN’s got legs. Stock just got ahead of itself. Cooling off is essential. Not easy to watch but the climb was too much too fast based on misguided assumptions made by blind investors.

explain how the rats were performing trapeeze acts and doing jumping jacks after getting the drug, and the human patients had highly muted responses? Is it because the patients in this experiment were deemed chronic?

Today's announcement was great. Meeting the primary endpoint along with a clear and demonstrable improvement in one of the secondary endpoints is a huge win. The stock's reaction is one of the 'challenges' of a mostly retail base. They (we) hold unrealistic expectations and panic when those expectations aren't met. I get it. Nonetheless, there's a reason they scheduled a presentation at ASIA: that community will get it and it will be viewed as a great achievement. After the conference call tomorrow afternoon there will likely be enhanced institutional interest. Remember, this was a proof of concept trial and, in this cohort, the concept was proven successfully. The chronic cohort consisted of people who have had little to no movement for years. To overcome the long-established scarring and atrophy is no small feat. They'll take what they've learned from this cohort and apply it to the P3 trial for enhanced success.

Looks that way! Yes.

The company wouldn't initiate an awareness campaign if they didn't have the goods. Next week's topline readout should be groundbreaking.

If you're just discovering this company and have a half-hour over the holiday weekend do yourself a favor and watch this video. NGENF CEO Mike Kelly was interviewed for the Oppenheimer Healthcare Conference in February where he gives a great overview of the company and its prospects. You'll be glad you did!

Yeah, I'm really wondering what market cap will be assigned to a very strong chronic topline. I guess we'll find out in 2 weeks.

We’ve seen nothing yet! Nervgen has what will become a breakthrough for science!

NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting

VANCOUVER, Canada, May 21, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that topline results from the chronic cohort of the ongoing Phase 1b/2a study of NVG-291 will be presented as an oral presentation at the 52nd American Spinal Injury Association Annual Scientific Meeting being held June 2-4, 2025 in Scottsdale, AZ.

“We are looking forward to completing the data analysis, unblinding the data, and presenting the first results from the chronic cohort in this initial proof-of-concept, double-blind, placebo-controlled clinical trial of NVG-291 in spinal cord injury (“SCI”),” stated Daniel Mikol, MD, Ph.D., NervGen’s Chief Medical Officer. “In this trial we have incorporated both clinical assessments as well as electrophysiological assessments of connectivity, as we feel this gives the highest probability of observing and characterizing an efficacy signal with NVG-291. We are hopeful that the results of the chronic cohort of our Phase 1b/2a trial may demonstrate, for the first time, the potential for NVG-291 to enable neural repair in individuals with SCI and will support further investigation of NVG-291 in SCI.”

https://nervgen.com/nervgen-pharma-to-present-topline-data-for-nvg-291-phase-1b-2a-chronic-cohort-study-at-the-american-spinal-injury-association-annual-scientific-meeting/

Dang. Great movement over the last couple of weeks. Thank goodness my first tranche of shares will be long-term in a couple of weeks. I hope the company details their plans to uplist shortly after the acute cohort results are released in early June - assuming they're positive. Based on MK's investor presentations this year, it seems highly probable that they are.

Looking good!
NGENF

Clinicaltrials.gov was updated a couple of days ago. Primary completion now 3/26.

https://clinicaltrials.gov/study/NCT05965700

How does the company tell us at the end of the third quarter that they are "nearing completion" of enrollment, yet here we are at the end of the 4th quarter and still no word on complete enrollment? It's only a 20-person trial; why the difficulties?

Q3 was their 'goal' for enrollment in the PH 1/2A study..

IF they say they saw improvement in motor skills (ie, its working)??

Guessing the fda will require a PH 3 of some sort, even if this does help people
and shows no safety issue (another one ATNM has something that works, but the fda
is making them do a new PH 3 trial, that denys people that could benefit from their
development from helping save/make their lives better)

So guessing even if this shows it works, can help folks get better, the fda will
force them to do a PH 3 which means a few more years.. Damn..

TIMELINE to being POTENTIALLY REWARDED??

for the current spinal recovery trials: at least 2 years??
got to finish the PH 2, and if the FDA makes them do at least a
partial PH 3? Looking at 2 years for those results (??)

on the others? Well over 2 years by the time the PH 1 is run and then...

Best they can hope for is that the safety profile and that there is no doubt
it works is to get 'conditionally approved' for usage with a parallel PH 3 to
observe to monitor whether or not the 'results' last, don't fade..

disclaimer: don't own any. Having a hard time understanding why IF
this LIN character is right, why the institutions
own so little of the shares. (reportedly 0% of the shares).. afterall, they
have a history of buying and holding to see what might happen in the next 5 years

Lin's comments in the Taylor interview just posted are big. He is saying, that he knows of a patients, via his mother, who son has gained significant, meaningful mobility. In fact, substantial mobility. He is also saying there is scuttlebutt and buzz around the patient group taking 291 -- their families and friends, which if you listen to it, means the drug is working. Working quite meaningfully. As he remarks, the patients themselves cannot say stuff, but they can share how they are doing with friends and family. And the F and F themselves are under no contract or agreement Not to communicate about the progress, if any. And the F and F's are themselves talking about real progress. SuBstantial progress, and this is why Lin is saying this is a trillion dollar opportunity.

Mike Kelly interview recently.

https://m.soundcloud.com/biotechguru/how-nervgen-is-developing-novel-treatments-to-repair-damage-to-the-nervous-system

A TRILLION DOLLAR opportunity, with Ngenf, having today a 200 million dollar cap, suggest s an eventual price for the shares up above the heavens and into the stratosphere. Lin suggests it will be the new Eli Lilly. I will settle for 1/20th of that.

Jay Taylor and Super Investor Chen Lin start about Nervgen at the 13.40 minute mark. And Lin is following his old Sarpeta Model where he bought that stock in the low single digits. He himself related years ago, that he actually flew to the home of the first patient treated, who could not walk, and saw with his own two eyes, that after receiving the SRPT drug, the young patient could walk. Chen related in a Jay Taylotr podcast, "What could I say. I saw him, and he could walk!" Lin perhpas made 50X his original investment, and SRPT stock today is 150 bucks a share.
And if you listen to him carefully, you see that he is pretty much following the same formula with Nervgen, which he sounds far more excited about, calling it a 'TRILLION DOLLAR OPPORTUNITY"

https://open.substack.com/pub/taylorjay/p/the-surrender-announcement-for-those?r=ym89d&utm_medium=ios
Listen @13:30

fyi ..https://neurosciencenews.com/glial-cells-neurogenesis-26408/

Today was a good day, the chart was simply too steep. I doubt Nergen will ever trade again below 2 bucks. The chart and story look very good going forward, My 2dc